STAT6 degrader advances into clinic

Research evidence excerpt

STAT6 degrader advances into clinic

Update

July 30, 2026 07:49 PM GMT

Morgan Stanley & Co. LLCMNurix Therapeutics Inc. | North America Terence C Flynn, Ph.D.

Equity Analyst

STAT6 degrader advances into Terence.Flynn@morganstanley.comAlexander Yevdokimov, Ph.D. +1 212 761-2230

Research Associate

Alexander.Yevdokimov@morganstanley.com +1 212 761-2167

clinic Damien H Kerner

Damien.H.Kerner@morganstanley.com +1 212 761-3829

NRIX's partner, Sanofi (covered by Sarita Kapila) has recently advanced NX-3911/

Hailey Horowitz

SAR448272, a STAT6 degrader into the clinic (LINK). We view this as an Research Associate

incremental positive for the program, NRIX's targeted protein degradation platform, Hailey.Horowitz@morganstanley.com +1 212 761-5264

Chris Yu, J.D., Ph.D.

and the stock. The STAT6 program is not in our NRIX model and could represent a Equity Analyst

source of upside to our estimates. Chris.L.Yu@morganstanley.com +1 212 761-2535

Connor M Massari

The trial is a first-in-human Ph1 study of the drug, structured as a single-ascending- Equity Analyst

Connor.Massari@morganstanley.com +1 212 761-2417

dose and multiple-ascending-dose (SAD/MAD) protocol. It plans to enroll

Morgan Stanley India Company Private Limited+

approximately 147 participants — both healthy volunteers and patients, male and

Saket Agarwal

female, spanning ages 18–64 and 65+ — at a single site, Charité Research Research Associate

Organisation GmbH in Berlin, Germany. The study was authorized in Germany on Saket.Agarwal@morganstanley.com +91 22 6995-4012

June 19, 2026, began on July 21, 2026, and is currently ongoing and recruiting, with

Nurix Therapeutics Inc. (NRIX.O, NRIX US)

an estimated completion around Oct 2027. The public record classifies it under

Biotechnology | United States of America